Datasheet

Version: 2.0.0 Revision date: 07 Sep 2025



Human Transcription Factor p65 / NFKB3 (RELA) CLIA Kit

Catalogue No.:abx196082

Human Nuclear Factor Kappa B p65 (NF-кВ p65) Chemiluminescent Immunoassay (CLIA) Kit is a Chemiluminescent Immunoassay (CLIA) kit against Nuclear Factor Kappa B p65 (NF-кВ p65).

Target: Transcription Factor p65 / NFKB3 (RELA)

Reactivity: Human

Tested Applications: CLIA

Recommended dilutions: Optimal dilutions/concentrations should be determined by the end user.

Storage: Shipped at 4 °C. Upon receipt, store the kit according to the storage instruction in the kit's manual.

Validity: The validity for this kit is 6 months.

Stability: The stability of the kit is determined by the rate of activity loss. The loss rate is less than 5% within

the expiration date under appropriate storage conditions. To minimize performance fluctuations, operation procedures and lab conditions should be strictly controlled. It is also strongly suggested

that the whole assay is performed by the same user throughout.

UniProt Primary AC: Q04206 (UniProt, ExPASy)

Gene Symbol: RELA

GeneID: 5970

OMIM: 164014

HGNC: 9955

KEGG: hsa:5970

Ensembl: ENSG00000173039

String: <u>9606.ENSP00000384273</u>

Test Range: 31.2 pg/ml - 2000 pg/ml

Sensitivity: 18.8 pg/ml

1 of 2

Datasheet

Version: 2.0.0 Revision date: 07 Sep 2025



Standard Form: Lyophilized

Detection Method: Chemiluminescent

Assay Type: Sandwich

Assay Data: Quantitative

Sample Type: Serum, plasma and other biological fluids.

Note: THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR

THERAPEUTIC PROCEDURES.

The range and sensitivity is subject to change. Please contact us for the latest product information. For accurate results, sample concentrations must be diluted to mid-range of the kit. If you require a specific range, please contact us in advance or write your request in your order comments. Please note that our kits are optimised for detection of native samples, rather than recombinant proteins. We are unable to guarantee detection of recombinant proteins, as they may have

different sequences or tertiary structures to the native protein.

2 of 2